PharmAust Limited Overview
PharmAust Limited (ASX: PAA) is a new player in Australia’s rapidly growing
pharmaceutical industry. Following the launch of its prospectus in October 2004, PharmAust
successfully raised $5.5 million, closing early oversubscribed. No adviser options have been
issued.
PharmAust is a unique vertically integrated pharmaceutical business that will take part in a
range of activities, from contract drug discovery and development to product manufacturing,
as well as sales and marketing of healthcare & pharmaceutical products.
PharmAust has an exclusive marketing and distribution agreement with pharmaceuticals
manufacturer, Xepa-Soul Pattinson (Xepa), a subsidiary of Malaysia’s largest healthcare
company, Apex Healthcare. This agreement enables 100% owned subsidiary PharmAust
Manufacturing to take advantage of patent arbitrage opportunities between Malaysia and
Australia for the import and sale of patent expired medicines otherwise known as generics
into Australia.
PharmAust Manufacturing has now also successfully acquired and renamed Ramprie
Laboratories, a WA-based pharmaceutical manufacturer. This purchase allows PharmAust
Manufacturing Pty Ltd (PAM), to also manufacture products from an existing base of 95
Australian registered and branded products along with the development, manufacture and
marketing of other existing Pharmaust Manufacturing brands along with the continuation of
contract manufacturing services for others.
PharmAust’s other key subsidiary, Epichem Pty Ltd currently provides contract chemistry
services alongside its own intellectual property-generating research activities. Epichem
continues to rapidly expand to keep pace with the influx of contracts, with five additional
chemists having joined the company since it opened in February 2004.
I
n partnership with Xepa and through its 100%-owned subsidiaries, Epichem Pty Ltd and
PharmAust Manufacturing Pty Ltd, PharmAust will take part in a range of activities, from drug
discovery and contract synthesis, to the manufacture, marketing and distribution of healthcare
and over the counter products, as well as low cost generic drugs available on the
Pharmaceutical Benefit Scheme (PBS).
PharmAust’s focus is on the manufacture of pharmaceuticals for the Australian and
international market including:
• Generic prescription medication
• Over the counter medication
• Healthcare products
• Specialised hospital products
PharmAust will pursue a rapid growth strategy that will seek to diversify and expand its base
of supply contracts, customers and markets so that it is not reliant on any one product,
customer or market.
- Forums
- ASX - By Stock
- eho relisted today as paa
PharmAust Limited OverviewPharmAust Limited (ASX: PAA) is a new...
Featured News
Featured News
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online